Revolution Medicines Stock News

Companies Reporting Before The Bell • Lexicon Pharmaceuticals (NASDAQ: LXRX ) is estimated to report earnings for its fourth quarter. • Praxis Precision Medicine (NASDAQ: PRAX ) is likely to report earnings for its fourth quarter. • Blackstone Secured (NYSE: BXSL ) is likely to report quarterly earnings at $0.59 per share on revenue of $171.69 million. • Mersana Therapeutics (NASDAQ: MRSN ) is estimated to report earnings for its fourth quarter. • Partner Communications Co (NASDAQ: PTNR ) is expected to report earnings for its fourth quarter. • Daqo New Energy (NYSE: DQ ) is expected to report quarterly earnings at $4.58 per share on revenue of $698.65 million. • Easterly Government Props (NYSE: DEA ) is likely to report quarterly earnings at $0.10 per share on revenue of $72.20 million. • Aurinia Pharmaceuticals (NASDAQ: AUPH ) is expected to report earnings for its fourth quarter. • Kosmos Energy (NYSE: KOS ) is estimated to report quarterly earnings at $0.15 per share on revenue of $380.

In last trading session, Revolution Medicines Inc. (NASDAQ:RVMD) saw 0.71 million shares changing hands with its beta currently measuring 0. Company’s recent per share price level of $19.82 trading at $0.06 or 0.30% at ring of the bell on the day assigns it a market valuation of $1.47B. That closing price of RVMD’s stock is … Revolution Medicines Inc. (NASDAQ:RVMD) Down -8.49% Over The Past 30 Days: Any Troubles Ahead? Read More »

Conference Call and Webcast Scheduled for Monday, February 28, 2022, at 4:30 p.m. Eastern Time Conference Call and Webcast Scheduled for Monday, February 28, 2022, at 4:30 p.m. Eastern Time

Conference Call and Webcast Scheduled for Monday, February 28, 2022, at 4:30 p.m. Eastern Time Conference Call and Webcast Scheduled for Monday, February 28, 2022, at 4:30 p.m. Eastern Time

Conference Call and Webcast Scheduled for Monday, February 28, 2022, at 4:30 p.m. Eastern Time Conference Call and Webcast Scheduled for Monday, February 28, 2022, at 4:30 p.m. Eastern Time

REDWOOD CITY, Calif., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, tod

RAS(ON) Inhibitor Pipeline Expands with Advancement of Two New Drug Candidates; Development-Stage Portfolio Covers RAS Drivers of Majority of RAS-Addicted Cancers

Shares of Revolution Medicines, Inc. (NASDAQ:RVMD) gapped up before the market opened on Monday . The stock had previously closed at $24.63, but opened at $25.43. Revolution Medicines shares last traded at $25.15, with a volume of 1,038 shares traded. A number of analysts recently issued reports on RVMD shares. Zacks Investment Research upgraded shares []

Revolution Medicines (NASDAQ:RVMD) and Checkmate Pharmaceuticals (NASDAQ:CMPI) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, risk, valuation, profitability and institutional ownership. Profitability This table compares Revolution Medicines and Checkmate Pharmaceuticals net margins, return on equity and []

REDWOOD CITY, Calif., Nov. 24, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted drugs to inhibit frontie

REDWOOD CITY, Calif., Nov. 24, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted drugs to inhibit frontier targets that drive and sustain RAS-addicted cancers, today announced that the company will participate in the 4 th Annual Evercore ISI HealthCONx Conference. Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines, will be the featured participant in a fireside chat at the event.

First Trust Advisors LP lessened its position in Revolution Medicines, Inc. (NASDAQ:RVMD) by 94.5% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 12,387 shares of the companys stock after selling 212,354 shares during the period. First Trust Advisors LPs []

Revolution Medicines, Inc. (NASDAQ:RVMD) shares gapped down prior to trading on Monday . The stock had previously closed at $30.10, but opened at $29.13. Revolution Medicines shares last traded at $29.75, with a volume of 1,290 shares trading hands. RVMD has been the subject of several research analyst reports. Zacks Investment Research raised Revolution Medicines […]

Metropolitan Life Insurance Co NY grew its holdings in Revolution Medicines, Inc. (NASDAQ:RVMD) by 150,336.4% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 16,548 shares of the companys stock after buying an additional 16,537 shares during the period. Metropolitan Life Insurance Co NYs holdings []